Kezar Life (KZR) unusual action is selling 2000 July $10 puts to buy 2000 of the $17.5/$25 call spreads. KZR is an $850M Biotech. Wells Fargo started shares Overweight in December highlighting two key derisking events in Q2, for KZR-616, a selective immunoproteosome inhibitor, that is being developed for autoimmune diseases